Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Breast Neoplasms 522Neoplasms 470Carcinoma, Non-Small-Cell Lung 393Prostatic Neoplasms 302Colorectal Neoplasms 296Lung Neoplasms 259Neoplasm Metastasis 217Ovarian Neoplasms 198Leukemia, Myeloid, Acute 194Pancreatic Neoplasms 185Multiple Myeloma 172Squamous Cell Carcinoma of Head and Neck 133Recurrence 132Stomach Neoplasms 129Brain Neoplasms 126Melanoma 123Carcinoma, Hepatocellular 123Endometrial Neoplasms 120Glioblastoma 118Triple Negative Breast Neoplasms 111Precursor Cell Lymphoblastic Leukemia-Lymphoma 105Hematologic Neoplasms 99Head and Neck Neoplasms 97Carcinoma, Renal Cell 96Lymphoma 93Urinary Bladder Neoplasms 90Sarcoma 90Glioma 88Lymphoma, Large B-Cell, Diffuse 81Small Cell Lung Carcinoma 80

Interventions

enzalutamide 1darolutamide 1cabazitaxel 1apalutamide 1Prednisone 1Docetaxel 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Recruiting × Metastatic Castration-resistant Prostate Neoplasms × 90 days × Clear all
NCT05818683 2026-06-05

A Study of Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer

Janssen Research & Development, LLC

Phase 1 Recruiting
300 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Neoplasms

NCT07164443 2026-06-05

KLK2-comPAS

Janssen Research & Development, LLC

Phase 3 Recruiting
663 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡